Skip to content
Study details
Enrolling now

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

UCB Biopharma SRL
NCT IDNCT07290036ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

392

Study length

about 2.6 years

Ages

18+

Locations

20 sites in AZ, CA, CO +9

What this study is about

This trial is testing different ways to give bimekizumab, either intravenously or subcutaneously. The goal is to see if both methods are safe and move similarly throughout the body over time.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Bimekizumab regimen 1 iv
  • 2.Receive Bimekizumab regimen 2 iv
  • 3.Take Bimekizumab regimen 3 sc

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

bimekizumab

Drug routes

infusion

Endpoints

Secondary: Occurrence of TEAEs leading to withdrawal of study intervention, Occurrence of treatment-emergent Adverse Events (TEAEs) from Baseline to the end of Safety Follow-Up (SFU) Visit, Occurrence of treatment-emergent Serious Adverse Events (SAEs) from Baseline to the end of SFU Visit

Body systems

Dermatology